20 articles
A phase III trial of 408 men finds metformin does not delay prostate cancer progression during active surveillance — and may worsen outcomes in obese patients.
A 1.6-million-person cohort study finds metformin neither prevents AMD development nor slows progression to advanced disease stages.
A comprehensive review reveals metformin's polypharmacological mechanisms—from AMPK activation to gut microbiome remodeling—that may delay aging and enhance cancer immunotherapy.
Six-month trial finds diabetes drug metformin significantly reduces knee pain compared to placebo in people with osteoarthritis and excess weight.
A major review challenges the evidence behind metformin as a longevity drug, exposing methodological flaws in landmark studies.
A massive 860,000-patient multinational study finds metformin users face significantly lower delirium and mortality risk than those on DPP-4 inhibitors.
Research reveals how the diabetes drug metformin may extend lifespan and healthspan through multiple molecular pathways.
A 2025 narrative review examines metformin's benefits, risks, and sex-specific efficacy for prediabetic women navigating the menopausal transition.
Large UK study reveals metformin users have dramatically lower rates of dangerous DNMT3A mutations that lead to blood cancer.
A sweeping 2025 review traces metformin from its 1922 synthesis to its emerging roles in cancer, aging, and longevity.
A landmark RCT of 5,047 type 2 diabetics finds GLP-1 agonists linked to fewer hospitalizations than other second-line therapies.
New review maps metformin's complex pathways beyond diabetes, showing how it targets cancer and aging through AMPK, mTOR, and mitochondrial mechanisms.
Large randomized trial finds metformin doesn't slow placental aging, challenging its potential as anti-aging therapy during pregnancy.
A landmark Nature study shows metformin can suppress the clonal advantage of DNMT3A-mutant blood stem cells, potentially preventing leukemia progression.
New research reveals metformin's complex effects on aging - protecting frail adults while potentially limiting muscle gains in active individuals.
A large real-world study finds GLP-1 drugs semaglutide and tirzepatide dramatically reduce heart failure hospitalization and death in HFpEF patients.
Large study finds diabetes drug metformin only slightly slows harmful blood cell mutations, questioning its use for cancer prevention.
A phase 2 trial finds tesamorelin reduces abdominal obesity in virally suppressed HIV patients but shows no significant cognitive improvement.
Combining metformin and berberine outperforms either drug alone in reversing NAFLD by powerfully activating the AMPK–SREBP1–FASN lipid-regulation axis.
A landmark JCI review maps the expanding pharmacological arsenal for MASH, from GLP-1 agonists to triple receptor therapies and precision medicine.
